{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:29:28Z","timestamp":1781155768038,"version":"3.54.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Progressive multifocal leukoencephalopathy is a demyelinating CNS disorder. Reactivation of John Cunningham virus leads to oligodendrocyte infection with lysis and consequent axonal loss due to demyelination. Patients usually present with confusion and seizures. Late diagnosis and lack of adequate therapy options persistently result in permanent impairment of brain functions. Due to profound T cell depletion, impairment of T-cell function and potent immunosuppressive factors, allogeneic hematopoietic cell transplantation recipients are at high risk for JCV reactivation. To date, PML is almost universally fatal when occurring after allo-HCT.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>To optimize therapy specificity, we enriched JCV specific T-cells out of the donor T-cell repertoire from the HLA-identical, anti-JCV-antibody positive family stem cell donor by unstimulated peripheral apheresis [1]. For this, we selected T cells responsive to five JCV peptide libraries via the Cytokine Capture System technology. It enables the enrichment of JCV specific T cells via identification of stimulus-induced interferon gamma secretion.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Despite low frequencies of responsive T cells, we succeeded in generating a product containing 20 000 JCV reactive T cells ready for patient infusion. The adoptive cell transfer was performed without complication. Consequently, the clinical course stabilized and the patient slowly went into remission of PML with JCV negative CSF and containment of PML lesion expansion.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>We report for the first time feasibility of generating T cells with possible anti-JCV activity from a seropositive family donor, a variation of virus specific T-cell therapies suitable for the post allo transplant setting. We also present the unusual case for successful treatment of PML after allo-HCT via virus specific T-cell therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12967-020-02337-5","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T14:03:06Z","timestamp":1587477786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes"],"prefix":"10.1186","volume":"18","author":[{"given":"M. J.","family":"Steinhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Wiercinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. U.","family":"Grigoleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Da-Via","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Meckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Nickel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. C.","family":"Krummenast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hopkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Weissbrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"M\u00fcllges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Stoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. M.","family":"Kort\u00fcm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bonig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"issue":"6","key":"2337_CR1","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1111\/trf.12506","volume":"54","author":"M Schulz","year":"2014","unstructured":"Schulz M, Bialleck H, Thorausch K, Bug G, Dunzinger U, Seifried E, et al. Unstimulated leukapheresis in patients and donors: comparison of two apheresis systems. Transfusion. 2014;54(6):1622\u20139. https:\/\/doi.org\/10.1111\/trf.12506.","journal-title":"Transfusion"},{"issue":"6","key":"2337_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/1756285615602832","volume":"8","author":"D Pavlovic","year":"2015","unstructured":"Pavlovic D, Patera AC, Nyberg F, Gerber M, Liu M. Progressive Multifocal Leukeoncephalopathy C. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord. 2015;8(6):255\u201373. https:\/\/doi.org\/10.1177\/1756285615602832.","journal-title":"Ther Adv Neurol Disord"},{"key":"2337_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ijid.2014.03.1381","volume":"26","author":"I Avivi","year":"2014","unstructured":"Avivi I, Wittmann T, Henig I, Kra-Oz Z, Szwarcwort Cohen M, Zuckerman T, et al. Development of multifocal leukoencephalopathy in patients undergoing allogeneic stem cell transplantation-can preemptive detection of John Cunningham virus be useful? Int J Infect Dis. 2014;26:107\u20139. https:\/\/doi.org\/10.1016\/j.ijid.2014.03.1381.","journal-title":"Int J Infect Dis"},{"issue":"15","key":"2337_CR4","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1056\/NEJMoa1801540","volume":"379","author":"M Muftuoglu","year":"2018","unstructured":"Muftuoglu M, Olson A, Marin D, Ahmed S, Mulanovich V, Tummala S, et al. Allogeneic BK virus-specific T cells for progressive multifocal leukoencephalopathy. N Engl J Med. 2018;379(15):1443\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1801540.","journal-title":"N Engl J Med"},{"issue":"7","key":"2337_CR5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/bmt.2010.221","volume":"46","author":"A Balduzzi","year":"2011","unstructured":"Balduzzi A, Lucchini G, Hirsch HH, Basso S, Cioni M, Rovelli A, et al. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant. 2011;46(7):987\u201392. https:\/\/doi.org\/10.1038\/bmt.2010.221.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2337_CR6","doi-asserted-by":"publisher","first-page":"e0211927","DOI":"10.1371\/journal.pone.0211927","volume":"14","author":"H Nahi","year":"2019","unstructured":"Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G, et al. Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. PLoS One. 2019;14(2):e0211927. https:\/\/doi.org\/10.1371\/journal.pone.0211927.","journal-title":"PLoS One"},{"issue":"6","key":"2337_CR7","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1714678.","journal-title":"N Engl J Med"},{"issue":"1","key":"2337_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjh.15433","volume":"185","author":"AJ Johnsrud","year":"2019","unstructured":"Johnsrud AJ, Johnsrud JJ, Susanibar SA, Kamimoto JJ, Kothari A, Burgess M, et al. Infectious and immunological sequelae of daratumumab in multiple myeloma. Br J Haematol. 2019;185(1):187\u20139. https:\/\/doi.org\/10.1111\/bjh.15433.","journal-title":"Br J Haematol"},{"issue":"15","key":"2337_CR9","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, et al. PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology. 2013;80(15):1430\u20138. https:\/\/doi.org\/10.1212\/WNL.0b013e31828c2fa1.","journal-title":"Neurology"},{"issue":"5","key":"2337_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1086\/520514","volume":"196","author":"S Verma","year":"2007","unstructured":"Verma S, Cikurel K, Koralnik IJ, Morgello S, Cunningham-Rundles C, Weinstein ZR, et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis. 2007;196(5):709\u201311. https:\/\/doi.org\/10.1086\/520514.","journal-title":"J Infect Dis"},{"key":"2337_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jns.2016.02.011","volume":"362","author":"G Ellrichmann","year":"2016","unstructured":"Ellrichmann G, Behrendt V, Grunwald C, Schlottmann R, Lukas C, Gold R. Cidofovir for treatment of progressive multifocal leukoencephalopathy in a newly diagnosed sarcoidosis patient - a valid therapeutic option? J Neurol Sci. 2016;362:341\u20133. https:\/\/doi.org\/10.1016\/j.jns.2016.02.011.","journal-title":"J Neurol Sci"},{"issue":"4","key":"2337_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/vox.12291","volume":"109","author":"M Bunos","year":"2015","unstructured":"Bunos M, Hummer C, Wingenfeld E, Sorg N, Pfirrmann V, Bader P, et al. Automated isolation of primary antigen-specific T cells from donor lymphocyte concentrates: results of a feasibility exercise. Vox Sang. 2015;109(4):387\u201393. https:\/\/doi.org\/10.1111\/vox.12291.","journal-title":"Vox Sang"},{"issue":"4","key":"2337_CR13","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s13365-015-0414-3","volume":"22","author":"DP Miskin","year":"2016","unstructured":"Miskin DP, Herman ST, Ngo LH, Koralnik IJ. Predictors and characteristics of seizures in survivors of progressive multifocal leukoencephalopathy. J Neurovirol. 2016;22(4):464\u201371. https:\/\/doi.org\/10.1007\/s13365-015-0414-3.","journal-title":"J Neurovirol"},{"issue":"1","key":"2337_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13045-019-0701-1","volume":"12","author":"T Kaeuferle","year":"2019","unstructured":"Kaeuferle T, Krauss R, Blaeschke F, Willier S, Feuchtinger T. Strategies of adoptive T-cell transfer to treat refractory viral infections post allogeneic stem cell transplantation. J Hematol Oncol. 2019;12(1):13.","journal-title":"J Hematol Oncol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02337-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-020-02337-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02337-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:18:01Z","timestamp":1618964281000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-020-02337-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2337"],"URL":"https:\/\/doi.org\/10.1186\/s12967-020-02337-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"4 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We have written consent to participate by the patient and his relatives. An ethics approval was not filed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We have written consent to participate and for publishing by the patient and his relatives.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HB has received research support and speakers\u2019 fees from Miltenyi Biotech, proprietors of the selection technology. The other authors report no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"177"}}